ZYBERNO
Stock Report
Updated Sep 1, 2026

PURE Bioscience, Inc. (PURE)

Materials • OTC

$0.08

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
12.0/100
POOR BUSINESS
PURE Bioscience, Inc. (PURE) scores 12/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-79.2%)
Return on Capital (Capital Efficiency):CRITICAL (-249.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

PURE Bioscience, Inc. (PURE) stock report — Zyberno Score 12/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.08
Market Cap:$8.76M

Valuation Multiples (2)

P/S Ratio:3.62x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$7.78M

Price Action & Momentum (3)

Momentum Percentile:15 / 100
% of 52-Week High:71.8%
B. Profitability Assessment

Return Metrics (4)

ROA:-192.2%
Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.4%

Margin Analysis (3)

Operating Margin Ttm:-79.2%
Net Margin Ttm:-91.2%
Ebitda Margin:-79.1%

TTM Performance (3)

Gross Margin Ttm:58.9%
Operating Margin Ttm:-79.2%
Net Margin Ttm:-91.2%

Yield Metrics (2)

Earnings Yield:-$37.50
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-275.0%
Latest Earnings Filed:2026-06-15

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):7.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.42x
Quick Ratio:0.36x
Cash Ratio:0.27x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-5.83x
Times Interest Earned:-5.83

Capital Structure (4)

Working Capital:-2,105,000.00
Cash And Cash Equivalents:983,000.00
Long Term Debt:$0.00
Net Debt:-$983.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $2.42M
Linear Growth: 7.3%
📊 Click to view full PURE Revenue analysis & methodology →
Cost Of Revenue Ttm:$997.00K

Profitability Breakdown (2)

Gross profit TTM: $1.43M
Linear Growth: 17.0%
📊 Click to view full PURE Gross Profit analysis & methodology →
-$1.92M

Bottom Line Performance (3)

-$2.21M
Income Before Tax:$0.00
Ebitda Ttm:-1,914,000.00

Operating Expenses (5)

Operating Expenses:3,341,000.00
R And D Expense:312,000.00
Sga Expense:3,029,000.00
Income Tax Expense:$0.00
Interest Expense:390,000.00

Expense Ratios (3)

R And D To Revenue Percentage:61.7%
Sga To Revenue Percentage:598.6%
Ebitda Margin:-79.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.56M
Current Assets:$1.55M
Ppe Net:9,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,397,000.00
Current Liabilities:3,654,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$5.84M
Retained Earnings:-$140.87M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:242,000.00
Inventory:232,000.00
Accounts Payable:719,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:55,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.76M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$350.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.03
-$0.03
Earnings Per Share Ttm:-$0.02

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.02
Operating Cash Flow Per Share:-$0.02

Book Value & Capital (2)

Book Value Per Share:-$0.05
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:2.11x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:10.00x
Days Sales Outstanding Ttm:36.52

Inventory Management (2)

Inventory Turnover Ttm:4.30x
Days Inventory Outstanding Ttm:84.93

Payables & Cash Cycle (2)

Days Payable Outstanding:263.22
Cash Conversion Cycle:-141.77
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):7.3%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):17.0%
Book Value Growth Rate (Linear):-16.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:PURE
Company Name:PURE Bioscience, Inc.
Sector:Materials
Industry:Miscellaneous Chemical Products
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:110.83M
Shares Outstanding Basic:110.83M
Shares Outstanding Diluted:110.83M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:08:43 UTC
Data Timestamp:2026-08-21T18:57:22.059771
Scroll to Top